Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
出版年份 2018 全文链接
标题
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
作者
关键词
-
出版物
Nature Communications
Volume 9, Issue 1, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-09-24
DOI
10.1038/s41467-018-05564-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- Overall survival in BRCA1 or RAD51C methylated vs mutated ovarian carcinoma following primary treatment with platinum chemotherapy
- (2017) S.S. Bernards et al. GYNECOLOGIC ONCOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
- (2017) Paz Polak et al. NATURE GENETICS
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and aBRCAmutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
- (2016) Ursula A. Matulonis et al. CANCER
- The BRCA1- 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
- (2016) Y. Wang et al. CANCER RESEARCH
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inherited Mutations in Women With Ovarian Carcinoma
- (2016) Barbara M. Norquist et al. JAMA Oncology
- Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells
- (2015) Steven Busschots et al. EXPERIMENTAL CELL RESEARCH
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- HISAT: a fast spliced aligner with low memory requirements
- (2015) Daehwan Kim et al. NATURE METHODS
- High-Throughput Amplicon-Based Copy Number Detection of 11 Genes in Formalin-Fixed Paraffin-Embedded Ovarian Tumour Samples by MLPA-Seq
- (2015) Olga Kondrashova et al. PLoS One
- HTSeq--a Python framework to work with high-throughput sequencing data
- (2014) S. Anders et al. BIOINFORMATICS
- BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
- (2014) I. Ruscito et al. EUROPEAN JOURNAL OF CANCER
- Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
- (2014) Poorval M. Joshi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts
- (2014) Monique D. Topp et al. Molecular Oncology
- Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations
- (2013) J. George et al. CLINICAL CANCER RESEARCH
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
- (2013) Kathryn P. Pennington et al. CLINICAL CANCER RESEARCH
- BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation
- (2013) Britta Stordal et al. Molecular Oncology
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evaluating cell lines as tumour models by comparison of genomic profiles
- (2013) Silvia Domcke et al. Nature Communications
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary culture and immortalization of human fallopian tube secretory epithelial cells
- (2012) Alison M Karst et al. Nature Protocols
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Whole-exome sequencing for finding de novo mutations in sporadic mental retardation
- (2011) Peter N Robinson GENOME BIOLOGY
- Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast Cancer
- (2010) E. M. Wong et al. Cancer Prevention Research
- BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors
- (2010) Jurgen Veeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
- (2010) Ahmed Ashour Ahmed et al. JOURNAL OF PATHOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma
- (2009) W. Sakai et al. CANCER RESEARCH
- Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas
- (2009) Elizabeth M Swisher et al. Molecular Cancer
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now